Bellerophon Therapeutics, Inc. (BLPH)
BLPHPrice: $0.01
Fair Value: 🔒
🔒score
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hyper... more
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of... more
Description
Shares
| Market Cap | $146,791 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Craig R. Jalbert CIRA |
| IPO Date | 2015-02-13 | CAGR | — |
| Employees | 18 | Website | bellerophon.com |
| Div. Yield | 158.04% | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | 158.04% |
BLPH chart loading...
Fundamentals
Technicals
| Enterprise Value | $481,700 | P/E Ratio | -0.01 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 0.05 |
| P/CF Ratio | -0.01 | P/FCF Ratio | -0.01 |
| EPS | $-0.89 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -1.64% | ROA | -2.5% |
| ROCE | -8.83% | Current Ratio | 1.4 |
| Quick Ratio | 1.4 | Cash Ratio | 1.28 |
| Debt/Equity | 0.08 | Interest Coverage | -165.81 |
| Altman Z Score | -77.24 | Piotroski Score | 2 |